To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Cerebrospinal fluid abaca… - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

Cerebrospinal fluid abacavir concentrations in HIV-positive patients following once-daily administration

Journal article
Authors A. Calcagno
C. Pinnetti
A. De Nicolo
E. Scarvaglieri
Magnus Gisslén
M. Tempestilli
A. D'Avolio
V. Fedele
G. Di Perri
A. Antinori
S. Bonora
Published in British Journal of Clinical Pharmacology
Volume 84
Issue 6
Pages 1380-1383
ISSN 0306-5251
Publication year 2018
Published at Institute of Biomedicine, Department of Infectious Medicine
Pages 1380-1383
Language en
Keywords abacavir, age, central nervous system, cerebrospinal fluid, pharmacokinetics, protease inhibitors, antiretroviral therapy, brain-barrier, plasma, drugs, pharmacokinetics, dolutegravir, combination, penetration, csf, Pharmacology & Pharmacy
Subject categories Pharmacology, Clinical pharmacology


Abacavir is a widely used nucleotide reverse transcriptase inhibitor, for which cerebrospinal fluid (CSF) exposure has been previously assessed in twice-daily recipients. We studied abacavir CSF concentrations in 61 and nine HIV-positive patients taking abacavir once daily and twice daily, respectively. Patients on once-daily abacavir had higher plasma and CSF concentrations (96 vs. 22ngml(-1), P = 0.038 and 123 vs. 49ngml(-1), P=0.038) but similar CSF-to-plasma ratios (0.8 vs. 0.5, P=0.500). CSF abacavir concentrations were adequate in patients receiving once-daily treatment.

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?